These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 12559253)
21. Screening for prostate cancer remains controversial. Neal DE; Donovan JL; Martin RM; Hamdy FC Lancet; 2009 Oct; 374(9700):1482-3. PubMed ID: 19664817 [No Abstract] [Full Text] [Related]
22. Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer. Kwiatkowski M; Klotz L; Hugosson J; Recker F Eur Urol; 2012 Apr; 61(4):851-4. PubMed ID: 22285762 [No Abstract] [Full Text] [Related]
23. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? Hoeltl W; Müller MM; Lunglmayr G J Urol; 2005 Jun; 173(6):2205; author reply 2205-6. PubMed ID: 15879895 [No Abstract] [Full Text] [Related]
24. Informed consent for PSA testing. Brown V J Fam Pract; 1996 Sep; 43(3):234-5. PubMed ID: 8797747 [No Abstract] [Full Text] [Related]
25. Recommendations on use of prostate-specific antigen for prostate cancer screening. Garnick MB JAMA; 2012 Apr; 307(13):1372; author reply 1372-4. PubMed ID: 22474197 [No Abstract] [Full Text] [Related]
26. Opportunistic testing: the death of informed consent? Davis DS Health Matrix Clevel; 2013; 23(1):35-54. PubMed ID: 23808098 [TBL] [Abstract][Full Text] [Related]
27. Prostate cancer screening--the evidence, the recommendations, and the clinical implications. Chou R; LeFevre ML JAMA; 2011 Dec; 306(24):2721-2. PubMed ID: 22203543 [No Abstract] [Full Text] [Related]
28. Prostate specific antigen: a useful screening test? Concato J Cancer J; 2000 Apr; 6 Suppl 2():S188-92. PubMed ID: 10803835 [TBL] [Abstract][Full Text] [Related]
29. Legal pitfalls in the diagnosis of prostate cancer. Dunn IB; Kirk D BJU Int; 2000 Aug; 86(3):304-7. PubMed ID: 10930937 [No Abstract] [Full Text] [Related]
30. Rationale for earlier and less frequent prostate cancer screening. Carter HB Urology; 2001 Nov; 58(5):639-41. PubMed ID: 11711328 [No Abstract] [Full Text] [Related]
31. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening. Schröder FH N Engl J Med; 2011 Nov; 365(21):1953-5. PubMed ID: 22029756 [No Abstract] [Full Text] [Related]
32. Promoting informed decision making about prostate cancer screening. Chan EC Compr Ther; 2001; 27(3):195-201. PubMed ID: 11569319 [TBL] [Abstract][Full Text] [Related]
33. Study Finds Overall Prostate Cancer Mortality Decreases with PSA Screening. Zolot J Am J Nurs; 2017 Dec; 117(12):16. PubMed ID: 29189229 [TBL] [Abstract][Full Text] [Related]
34. One man at a time--resolving the PSA controversy. McNaughton-Collins MF; Barry MJ N Engl J Med; 2011 Nov; 365(21):1951-3. PubMed ID: 22029758 [No Abstract] [Full Text] [Related]
35. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out. Brett AS; Ablin RJ N Engl J Med; 2011 Nov; 365(21):1949-51. PubMed ID: 22029759 [No Abstract] [Full Text] [Related]
37. ERSPC: features and preliminary results of France. Villers A; Malavaud B; Rebillard X; Bataille V; Iborra F BJU Int; 2003 Dec; 92 Suppl 2():27-9. PubMed ID: 14983950 [No Abstract] [Full Text] [Related]
38. Prostate cancer screening: a place for informed consent? Glodé LM Hosp Pract (Off Ed); 1994 Sep; 29(9):8, 11-2. PubMed ID: 7521881 [No Abstract] [Full Text] [Related]
39. Prostate-specific antigen: should patients receive information before having the test? Kirk D BJU Int; 2003 Aug; 92(3):185-6. PubMed ID: 12887462 [No Abstract] [Full Text] [Related]
40. [Regarding the duty of care of a general practitioner for a continuously increasing, elevated PSA level (OLG Koblenz, decision dated 18 June 2015 - 5 U 66/15)]. Dahm FJ Urologe A; 2016 Jul; 55(7):949-51. PubMed ID: 27335093 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]